Uniwersytet Jagielloński w Krakowie - Punkt LogowaniaNie jesteś zalogowany | zaloguj się
katalog przedmiotów - pomoc

Nuclear Receptors in Gene Regulation and Diseases

Informacje ogólne

Kod przedmiotu: WBt-BT140E Kod Erasmus / ISCED: (brak danych) / (0512) Biochemia
Nazwa przedmiotu: Nuclear Receptors in Gene Regulation and Diseases
Jednostka: Wydział Biochemii, Biofizyki i Biotechnologii
Grupy: Facultative subjects for 1 year Molecular Biotechnology - summer semester 2019/2020
Facultative Subjects in English at the FBBB - summer semester 2019/2020
Kursy do wyboru programu Study Abroad API
Punkty ECTS i inne: 3.00
zobacz reguły punktacji
Język prowadzenia: angielski

Zajęcia w cyklu "Semestr letni 2019/2020" (zakończony)

Okres: 2020-02-24 - 2020-06-14
Wybrany podział planu:


powiększ
zobacz plan zajęć
Typ zajęć: Wykład, 30 godzin więcej informacji
Koordynatorzy: Alicja Józkowicz
Prowadzący grup: Alicja Józkowicz
Lista studentów: (nie masz dostępu)
Zaliczenie: Przedmiot - Zaliczenie na ocenę
Ocena wliczana do średniej:

tak

Cele kształcenia:

(tylko po angielsku) Students will gain knowledge on basic features of nuclear receptors and medicines developed to target nuclear receptors. Special attention will be paid to the regulatory role of nuclear receptors in differentiation of stem cells and progenitor cells, their involvement in integration of responses to environmental or hormonal signals, and their applications as the molecular tools in biotechnology.

Efekty kształcenia:

(tylko po angielsku) After completing the course the students should have knowledge on:

* characteristics of nuclear receptors and their ligands

* evolution of nuclear receptors

* signaling networks coordinated by nuclear receptors that are essential for multicellular life and emerging role of orphan nuclear receptors

* medicines acting through regulation of nuclear receptors [BCH2K_W01, BT2K_W01]

* application of nuclear receptors in biotechnology [BCH2K_W04, BT2K_W04]


After completing the course the students should:

* understand what are the features of druggable targets

* be aware of the fundamental importance of basic research in development of drugs [BCH2K_U02, BT2K_U02]


After completing the course the student should understand the need of:

* continuous updating of knowledge on cell biology and drug development [BCH2K_K01, BT2K-K01]


Wymagania wstępne:

(tylko po angielsku) none

Forma i warunki zaliczenia:

zaliczenie z oceną

Metody sprawdzania i kryteria oceny efektów kształcenia uzyskanych przez studentów:

(tylko po angielsku) Single choice test evaluating the knowledge on nuclear receptors. Student can get 40 points and must obtain at least 24 to pass the evaluation.

Metody dydaktyczne - słownik:

Metody podające - prezentacja multimedialna
Metody podające - wykład informacyjny

Metody dydaktyczne:

(tylko po angielsku) * Expository method: lectures supported by multimedia presentations

* Problem-oriented methods: discussion on druggability of nuclear receptors


Bilans punktów ECTS:

(tylko po angielsku) 2 ECTS (1 ECTS/30 h of student time involvement) =

90 h of total working hours:


Participation in classes:

* lectures: 30 h


Individual work:

* learning on the subjects presented during lectures: 30 h



Sylabus przedmiotu dla studentów rozpoczynających studia od roku akademickiego 19/20:

Molecular Biotechnology

Skrócony opis: (tylko po angielsku)

Nuclear receptors are found in all animals, from mammals. These ligand-induced transcription factors have critical roles in nearly every aspects of physiology by transducing the effects of lipophilic molecules, e.g. steroids, retinoids, into transcriptional responses. Around 50 genes encoding nuclear receptors have been identified in human. Many of them are biomedically significant due to their roles in diseases such as breast and prostate cancers, leukemias, thyroid hormone resistance, obesity or diabetes. To date, some nuclear receptors have been identified as therapeutic targets for important drugs used in clinic. The course will cover basic concepts of nuclear receptors, and will give a knowledge about their role in pathogenesis and therapy of common human diseases.

Pełny opis: (tylko po angielsku)

Lectures:

* Nuclear receptors as ligand-activated transcription factors

* Co-activators, co-repressors and common heterodimeric partners of nuclear receptors

* Nuclear receptors in developing embryo

* Nuclear receptors in muscle adaptations

* Nuclear receptors in bone remodeling

* Nuclear receptors in adipogenesis and lipid metabolism

* Nuclear receptors in cardiovascular diseases

* Nuclear receptors in regulation of circadian rhythms

* Nuclear receptors in hormone-dependent cancers

* Nuclear receptors in hematopoiesis and leukemogenesis

* Gene expression of demand: nuclear receptors and their ligand in biotechnology

Literatura: (tylko po angielsku)

Examples of interesting articles for further reading:

* Evans RM, Mangelsdorf DJ. Nuclear receptors, RXR, and the Big Bang. Cell 2014; 157.

* Wu SP, Yu CT, Tsai SY, Tsai MJ. Choose your destiny: make a cell fate decision with COUP-TFII. J Steroid Biochem Mol Biol 2016; 157: 7–12.

* Kupr B, Schnyder S, Handschin C. Role of nuclear receptors in exercise-induced muscle adaptations.

Cold Spring Harb Perspect Med 2017; 7: a029835.

* Imai Y, Youn MY, Inoue K, Takada I, Kouzmenko A, Kato S. Nuclear receptors in bone physiology and diseases. Physiol Rev 2013; 93: 481–523.

* Schulman IG. Nuclear receptors as drug targets for metabolic disease. Adv Drug Deliv Rev 2010; 62: 1307–1315.

* Lee SD, Tontonoz P. Liver X receptors at the intersection of lipid metabolism and atherogenesis. Atherosclerosis 2015; 242: 29-36.

* Lefterova MI, Haakonsson AK, Lazar MA, Susanne Mandrup S. PPARγ and the global map of adipogenesis and beyond. Trends Endocrinol Metabol 2014; 25: 6.

* DuPont JJ, Jaffe IZ. The role of the mineralocorticoid receptor in the vasculature. J Endocrinol 2017; 234: 67–82.

* Marciano DP, Chang MR, Corzo CA, Goswami D, Lam VQ, Pascal BD, Griffin PR. The therapeutic potential of nuclear receptor modulators for treatment of metabolic disorders: PPARγ, RORs, and Rev-erbs. Cell Metabol 2014.

* Kojetin DJ, Burris TP. REV-ERB and ROR nuclear receptors as drug targets. Nat Rev Drug Discov 2014; 13: 197–216.

* Capper CP, Rae JM, Auchus RJ. The metabolism, analysis, and targeting of steroid hormones in breast and prostate cancer. Horm Cancer 2016; 7: 149–164.

* Chute JP, Ross JR, McDonnell DP. Minireview: nuclear receptors, hematopoiesis, and stem cells. Mol Endocrinol 2010; 24: 1–10.

* Zhang J, Zhao J, Jiang WJ, Xi-wei Shan XW, Xiao-mei Yang XM, Jian-gang Gao JG. Conditional gene manipulation: Cre-ating a new biological era. Biomed Biotechnol 2012; 13: 511-524.

Uwagi: (tylko po angielsku)

Presentations will be accessible.

Opisy przedmiotów w USOS i USOSweb są chronione prawem autorskim.
Właścicielem praw autorskich jest Uniwersytet Jagielloński w Krakowie.